UniQure's stock drops after FDA says insufficient evidence for Huntington's approval, causing plunge.

Unusual Whales
2025.12.04 15:28
On Thursday, UniQure stock experienced a significant decrease following news that the FDA has stated insufficient evidence for the approval of their Huntington's gene therapy. The rejection from the FDA has caused another drop in UniQure's stock, indicating a challenging situation for the company. This news emphasizes the uncertainty surrounding the fate of UniQure's treatment for Huntington's disease.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer